OptiNose (OPTN) Stock Price, News & Analysis

Company Overview

OptiNose, Inc. is a commercial-stage biopharmaceutical company headquartered in Yardley, Pennsylvania, that focuses on the development and commercialization of novel treatments for ear, nose and throat (ENT) diseases. Since its founding in 2004, OptiNose has built a platform technology that harnesses the patient’s own exhalation to deliver drug formulations directly to targeted regions within the nasal cavity. The company went public in 2015 and has since concentrated its efforts on addressing unmet needs in chronic sinonasal conditions.

The company’s lead product, XHANCE, is an FDA-approved intranasal spray that utilizes OptiNose’s proprietary exhalation delivery system to treat chronic rhinosinusitis with and without nasal polyps. By directing active drug particles past the nasal valve and into the sinuses, XHANCE aims to reduce inflammation and improve sinus ventilation more effectively than traditional nasal sprays. Beyond XHANCE, OptiNose is advancing additional pipeline candidates for allergic rhinitis, nonallergic rhinitis and other ENT indications, all leveraging the same novel delivery approach.

OptiNose primarily serves the U.S. market with a specialized commercial organization focused on education and support for ear, nose and throat specialists, allergists and primary care physicians. The company is also pursuing regulatory approvals and partnerships in Europe and other regions to broaden patient access to its therapies. In parallel, OptiNose continually invests in clinical trials and research collaborations to expand the indications for its exhalation delivery platform.

Led by a seasoned management team with extensive experience in pharmaceutical development, regulatory affairs and commercial operations, OptiNose is guided by a board of directors with a track record in advanced drug delivery and ENT therapeutics. The company’s leadership emphasizes strategic growth initiatives, patient-centric innovation and rigorous clinical science as it works to reshape treatment paradigms in sinonasal and related disorders.

Key Stats

• Today's Range: $9.60 to $9.60
• 50-Day Range: $9.38 to $9.71
• 52-Week Range: $4.82 to $19.50
• Volume: N/A
• Average Volume: 63,638 shs
• Market Capitalization: $97.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

OptiNose Stock Analysis - MarketRank™

OptiNose scored higher than 13% of companies evaluated by MarketBeat, and ranked 890th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

OptiNose has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

OptiNose has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OptiNose are expected to grow in the coming year, from ($3.22) to ($2.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OptiNose is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OptiNose is -2.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OPTN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OptiNose does not currently pay a dividend.

Dividend Growth

OptiNose does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -2.10

Short Interest

There is no current short interest data available for OPTN.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for OPTN on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OptiNose insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.30% of the stock of OptiNose is held by insiders.

Percentage Held by Institutions

85.60% of the stock of OptiNose is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OPTN Stock Analysis - Frequently Asked Questions

How have OPTN shares performed this year?

OptiNose's stock was trading at $6.68 at the start of the year. Since then, OPTN shares have increased by 43.7% and is now trading at $9.60.

How were OptiNose's earnings last quarter?

OptiNose, Inc. (NASDAQ:OPTN) released its earnings results on Tuesday, May, 13th. The company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by $0.27. The firm had revenue of $18.51 million for the quarter, compared to analysts' expectations of $17.70 million.

When did OptiNose's stock split?

OptiNose shares reverse split on Tuesday, December 31st 2024.The 1-15 reverse split was announced on Thursday, December 26th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did OptiNose IPO?

OptiNose (OPTN) raised $101 million in an initial public offering on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.

How do I buy shares of OptiNose?

Shares of OPTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of OptiNose own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OptiNose investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), GE Aerospace (GE), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/14/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OPTN
• CIK: 1494650
• Web: www.optinose.com
• Phone: (267) 364-3500
• Fax: N/A
• Employees: 190
• Year Founded: N/A

Price Target and Rating

• Average Price Target for OptiNose: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: -6.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.48 million
• Net Margins: -41.16%
• Pretax Margin: -41.16%
• Return on Equity: N/A
• Return on Assets: -27.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.79
• Quick Ratio: 0.72

Sales & Book Value

• Annual Sales: $81.86 million
• Price / Sales: 1.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($11.56) per share
• Price / Book: -0.83

Miscellaneous

• Outstanding Shares: 10,127,000
• Free Float: 9,829,000
• Market Cap: $97.22 million
• Optionable: Not Optionable
• Beta: -0.88